logo-loader
IXICO PLC

IXICO plc - Result of AGM

RNS Number : 1442O
IXICO plc
27 January 2023
 

 

27 January 2023

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

 

 

RESOLUTION

VOTES
FOR

%

VOTES
AGAINST

%

VOTES
TOTAL

% ISC VOTED

VOTES
WITHHELD

1

Reports and Accounts

 

26,812,002

99.96%

11,472

0.04%

26,823,474

55.48

9,231

2a

Re-election of Giulio Cerroni

 

26,821,033

99.96%

11,372

0.04%

26,832,405

55.49

300

2b

Election of Kate Rogers

26,675,515

99.95%

12,670

0.05%

26,688,185

55.20

144,520

3

Re-appointment of Auditors

 

26,808,776

99.94%

16,198

0.06%

26,824,974

55.48

7,731

4

Allotment of Securities

 

26,812,002

99.93%

19,681

0.07%

26,831,683

55.49

1,022

5

* Disapply Pre-Emption Provisions

26,674,807

99.92%

22,559

0.08%

26,697,366

55.22

135,339

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.    

 

For further information please contact:

 

IXICO plc

+44 (0)20 3763 7499

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 


 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Tamar Cranford-Smith (Sales)




About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.  

 

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

 

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGNKOBPBBKDCDB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO CTO on IXI platform upgrade, AI and expanding technology partnerships

IXICO PLC (LSE:IXI, OTC:PHYOF) chief technology officer Mark Austin talked with Proactive's Stephen Gunnion about the latest upgrade to its IXI platform, expanding technology partnerships and the growing role of artificial intelligence (AI) in neurological drug development. Austin explained...

7 hours, 45 minutes ago

2 min read